Alexion Pharmaceuticals, Inc. (ALXN) Shares Bought by Morgan Stanley

Morgan Stanley raised its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 112.0% during the first quarter, Holdings Channel reports. The firm owned 585,482 shares of the biopharmaceutical company’s stock after buying an additional 309,299 shares during the period. Morgan Stanley’s holdings in Alexion Pharmaceuticals were worth $70,983,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of ALXN. Caisse DE Depot ET Placement DU Quebec raised its position in Alexion Pharmaceuticals by 233.1% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 33,724 shares of the biopharmaceutical company’s stock valued at $4,093,000 after buying an additional 23,600 shares during the period. Dimensional Fund Advisors LP raised its position in Alexion Pharmaceuticals by 4.4% in the first quarter. Dimensional Fund Advisors LP now owns 321,459 shares of the biopharmaceutical company’s stock valued at $38,975,000 after buying an additional 13,679 shares during the period. Geode Capital Management LLC raised its position in Alexion Pharmaceuticals by 9.1% in the first quarter. Geode Capital Management LLC now owns 2,115,331 shares of the biopharmaceutical company’s stock valued at $256,086,000 after buying an additional 176,941 shares during the period. Vanguard Group Inc. raised its position in Alexion Pharmaceuticals by 3.1% in the first quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock valued at $1,754,034,000 after buying an additional 433,293 shares during the period. Finally, Guardian Life Insurance Co. of America raised its position in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the period. 94.40% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded up 0.931% during midday trading on Friday, hitting $127.405. 2,033,620 shares of the stock were exchanged. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $145.42. The firm’s 50-day moving average is $112.77 and its 200 day moving average is $122.35. The stock has a market cap of $28.61 billion, a price-to-earnings ratio of 60.698 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.33. The company had revenue of $870 million during the quarter, compared to analyst estimates of $826.63 million. Alexion Pharmaceuticals had a net margin of 14.52% and a return on equity of 11.72%. The business’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.11 EPS. Equities research analysts expect that Alexion Pharmaceuticals, Inc. will post $5.31 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first reported by Mideast Time and is owned by of Mideast Time. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.mideasttime.com/alexion-pharmaceuticals-inc-alxn-shares-bought-by-morgan-stanley/1805516.html.

Several equities analysts recently commented on the company. Leerink Swann reissued an “outperform” rating on shares of Alexion Pharmaceuticals in a report on Thursday. BidaskClub raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 14th. Credit Suisse Group set a $164.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, June 14th. Finally, J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 14th. Eight investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $161.38.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson bought 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The stock was acquired at an average cost of $116.72 per share, with a total value of $1,167,200.00. Following the completion of the purchase, the chief executive officer now directly owns 38,725 shares in the company, valued at $4,519,982. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The shares were acquired at an average cost of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 2,019,734 shares of company stock valued at $235,606,846. Company insiders own 4.35% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ALXN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.